Zero Applications at the National Audit — What the Scheme Is and Why No One Applied
When Korea overhauled its drug pricing system, it added a price premium for finished drugs made with active pharmaceutical ingredients (APIs) produced domestically. The goal was to reduce dependence on imported APIs and stabilize the supply chain.
At the 2026 National Assembly audit of the Health Insurance Review and Assessment Service (HIRA), however, it emerged that not a single company had applied for or received the premium. Lawmakers said the scheme had produced "zero incentive" for API self-sufficiency.
The problem is the eligibility rule. The premium currently applies only when the marketing authorization holder of the finished drug synthesizes the API itself, including the chemical conversion steps, at its own manufacturing site. Domestic APIs sourced from an affiliate or a specialist API maker do not count. Critics note that this ignores how Korea's industry actually works: API and finished-dose manufacturing have long been separate businesses.
The Dependence in Numbers
When a single API runs short, production of the finished drug stops, and that quickly becomes a shortage or supply discontinuation. Other governments treat this as a policy priority: the US is pursuing API stockpiling and onshoring, the EU is advancing a Critical Medicines Act, and Japan supports domestic production of antibiotic APIs.
Where Reform Talk Is Heading, and What Remains Uncertain
Options raised at the audit and by industry include:
That said, no revised rule has been finalized. Whether the requirement will change, and when, depends on follow-up announcements from the Ministry of Health and Welfare. Even if the rule is relaxed, companies will most likely still need documented proof that the API is domestic to qualify.
What SME Finished-Dose Manufacturers Should Do Now
1. Map your API supply chain
2. Estimate switching cost and time
3. Set product selection criteria
An Opportunity for API Manufacturers?
A relaxed rule could raise finished-dose makers' demand for domestic APIs. Price alone won't win contracts, though. Customers will take on the burden of a variation filing only if the supplier has solid GMP compliance and DMF capability.
Action Checklist and How KITIM Can Help
KITIM helps pharma and bio companies plan GMP readiness, regulatory variation strategy and access to government programs for API self-sufficiency. If you are reviewing your API sourcing or considering a switch to domestic APIs, contact the KITIM consulting team. We will work with you on an action plan tailored to your product portfolio.
